Sciwind is an internationally focused biotechnology company driven by scientific research, specializing in metabolic diseases, particularly fibrotic diseases. The company is dedicated to the development of innovative therapeutic products derived from biotechnology with unique intellectual property rights. Sciwind's main emphasis is on NASH, specifically steatohepatitis, liver inflammation, and liver fibrosis. The R&D team is comprised of professionals from the Recruitment Program of Global Experts, repatriates from overseas, and local experts who are specialized in the innovative drug research and development, encompassing drug design, process development, pharmacology, and toxicology.